JW Pharmaceutical Corp (001065) - Total Liabilities

Latest as of September 2025: ₩257.46 Billion KRW ≈ $174.47 Million USD

Based on the latest financial reports, JW Pharmaceutical Corp (001065) has total liabilities worth ₩257.46 Billion KRW (≈ $174.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 001065 net assets growth trend to track the company's year-over-year net asset growth rate.

JW Pharmaceutical Corp - Total Liabilities Trend (2014–2024)

This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data.

JW Pharmaceutical Corp Competitors by Total Liabilities

The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.

Company Country Total Liabilities
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
Turkey TL10.51 Billion
IVF Hartmann Holding AG
SW:VBSN
Switzerland CHF35.56 Million
CapsoVision, Inc. Common Stock
NASDAQ:CV
USA $4.90 Million
Beijing New Universal Science and Technology Co Ltd
SHE:300472
China CN¥1.06 Billion
Xinlong Holding Group Co Ltd
SHE:000955
China CN¥152.91 Million
AB Traction
ST:TRAC-B
Sweden Skr3.50 Million
Sphera Franchise Group SA MiFID Eligible Security
RO:SFG
Romania RON651.12 Million
VT GMP Co.Ltd
KQ:018290
Korea ₩93.15 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JW Pharmaceutical Corp market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.73 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.42 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JW Pharmaceutical Corp (2014–2024)

The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩275.11 Billion
≈ $186.44 Million
-27.53%
2023-12-31 ₩379.60 Billion
≈ $257.25 Million
-5.62%
2022-12-31 ₩402.21 Billion
≈ $272.57 Million
-9.52%
2021-12-31 ₩444.51 Billion
≈ $301.24 Million
+30.12%
2020-12-31 ₩341.62 Billion
≈ $231.51 Million
-0.44%
2019-12-31 ₩343.12 Billion
≈ $232.52 Million
+2.83%
2018-12-31 ₩333.68 Billion
≈ $226.13 Million
-7.34%
2017-12-31 ₩360.10 Billion
≈ $244.03 Million
-3.91%
2016-12-31 ₩374.76 Billion
≈ $253.97 Million
-3.43%
2015-12-31 ₩388.07 Billion
≈ $262.99 Million
+5.11%
2014-12-31 ₩369.22 Billion
≈ $250.21 Million
--

About JW Pharmaceutical Corp

KO:001065 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$335.70 Million
₩495.37 Billion KRW
Market Cap Rank
#14498 Global
#479 in Korea
Share Price
₩24650.00
Change (1 day)
-2.18%
52-Week Range
₩24650.00 - ₩30000.00
All Time High
₩88605.96
About

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more